Erlotinib + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Sep 1, 2006 → Jun 1, 2014
NCT ID
NCT00373425About Erlotinib + Placebo
Erlotinib + Placebo is a phase 3 stage product being developed by Astellas Pharma for Non-small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00373425. Target conditions include Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00402779 | Phase 3 | Completed |
| NCT00373425 | Phase 3 | Completed |
Competing Products
20 competing products in Non-small Cell Lung Cancer